Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology
Sisse R. Ostrowski
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorLouise Bochsen
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorNis A. Windeløv
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorJosé A. Salado-Jimena
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorInge Reynaerts
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorRaymond P. Goodrich
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorPär I. Johansson
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorSisse R. Ostrowski
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorLouise Bochsen
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorNis A. Windeløv
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorJosé A. Salado-Jimena
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorInge Reynaerts
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorRaymond P. Goodrich
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorPär I. Johansson
From the Section for Transfusion Medicine, Capital Region Blood Bank, and the Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, and CaridianBCT Biotechnologies, Lakewood, Colorado.
Search for more papers by this authorThis study was conducted under contract to CaridianBCT Biotechnologies, Lakewood, CO.
Abstract
BACKGROUND: Pathogen reduction technologies (PRTs) may influence the hemostatic potential of stored platelet (PLT) concentrates. To investigate this, buffy coat PLTs (BCPs) stored in PLT additive solution (SSP+) with or without Mirasol PRT treatment (CaridianBCT Biotechnologies) were compared by functional hemostatic assays.
STUDY DESIGN AND METHODS: We performed in vitro comparison of PRT (PRT-BCP) and control pooled-and-split BCPs (CON-BCP) after 2, 3, 6, 7, and 8 days' storage. Hemostatic function was evaluated with thrombelastography (TEG) and impedance aggregometry (Multiplate), the latter also in a sample matrix (Day 2) with or without addition of red blood cells (RBCs), control plasma, and/or PRT-treated plasma.
RESULTS: PRT treatment of 8-day-stored BCPs influenced clot formation (TEG) minimally, with reductions in maximum clot strength (maximum amplitude, p = 0.014) but unchanged initial fibrin formation (R), clot growth rate (α), and fibrinolysis resistance. In the absence of RBCs and plasma, PRT impaired aggregation (Multiplate) in stored BCPs, with reduced aggregation against thrombin receptor activating peptide-6 (p < 0.001), collagen (p = 0.014), adenosine 5′-diphosphate (p = 0.007), and arachidonic acid (p = 0.070). Addition of RBCs and PRT-treated or untreated plasma to PRT-BCP and CON-BCP, respectively, enhanced aggregation in both groups.
CONCLUSIONS: Mirasol PRT treatment of BCPs had a minimal influence on clot formation, whereas aggregation in the absence of RBCs and plasma was significantly reduced. Addition of RBCs and plasma increased agonist-induced responses resulting in comparable aggregation between PRT-BCP and CON-BCP. The clinical relevance for PLT function in vivo of these findings will be investigated in a clinical trial.
REFERENCES
- 1 Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003; 289: 959-62.
- 2 Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005; 19: 110-26.
- 3 Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006; 35: 5-17.
- 4 Maurer-Spurej E, Chipperfield K. Past and future approaches to assess the quality of platelets for transfusion. Transfus Med Rev 2007; 21: 295-306.
- 5 Holme S. In vitro assays used in the evaluation of the quality of stored platelets: correlation with in vivo assays. Transfus Apher Sci 2008; 39: 161-5.
- 6 Flisberg P, Rundgren M, Engstrom M. The effects of platelet transfusions evaluated using rotational thromboelastometry. Anesth Analg 2009; 108: 1430-2.
- 7 Apelseth TO, Bruserud O, Wentzel-Larsen T, Hervig T. Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. Transfusion 2010; 50: 766-75.
- 8 Salooja N, Perry DJ. Thrombelastography. Blood Coagul Fibrinolysis 2001; 12: 327-37.
- 9 Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008; 106: 1366-75.
- 10 Chakroun T, Gerotziafas GT, Seghatchian J, Samama MM, Hatmi M, Elalamy I. The influence of fibrin polymerization and platelet-mediated contractile forces on citrated whole blood thromboelastography profile. Thromb Haemost 2006; 95: 822-8.
- 11 Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3: 2039-43.
- 12 Johansson PI, Svendsen MS, Salado J, Bochsen L, Kristensen AT. Investigation of the thrombin-generating capacity, evaluated by thrombogram, and clot formation evaluated by thrombelastography of platelets stored in the blood bank for up to 7 days. Vox Sang 2008; 94: 113-8.
- 13 Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006; 32 Suppl 1: 32-8.
- 14 Johansson PI, Bochsen L, Andersen S, Viuff D. Investigation of the effect of kaolin and tissue factor-activated citrated whole blood, on clot forming variables, as evaluated by thromboelastography. Transfusion 2008; 48: 2377-83.
- 15 Johansson PI, Stissing T, Bochsen L, Ostrowski SR. Thrombelastography and tromboelastometry in assessing coagulopathy in trauma. Scand J Trauma Resusc Emerg Med 2009; 17: 45.
- 16 Sorensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements—an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005; 11 Suppl 1: 1-6.
- 17 Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Stahel PF, Vincent JL, Spahn DR. Management of bleeding following major trauma: an updated European guideline. Crit Care 2010; 14.
- 18 McGlasson DL, Fritsma GA. Whole blood platelet aggregometry and platelet function testing. Semin Thromb Hemost 2009; 35: 168-80.
- 19 Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-8.
- 20 Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods 1980; 3: 135-58.
- 21 Görlinger K, Jambor C, Hanke AA, Dirkmann D, Adamzik M, Hartmann M, Rahe-Meyer N. Perioperative coagulation management and control of platelet transfusion by point-of-care platelet function analysis. Transfus Med Hemother 2007; 34: 396-411.
- 22 Poston R, Gu J, Manchio J, Lee A, Brown J, Gammie J, White C, Griffith BP. Platelet function tests predict bleeding and thrombotic events after off-pump coronary bypass grafting. Eur J Cardiothorac Surg 2005; 27: 584-91.
- 23 Mengistu AM, Wolf MW, Boldt J, Rohm KD, Lang J, Piper SN. Evaluation of a new platelet function analyzer in cardiac surgery: a comparison of modified thromboelastography and whole-blood aggregometry. J Cardiothorac Vasc Anesth 2008; 22: 40-6.
- 24 Rahe-Meyer N, Winterhalter M, Hartmann J, Pattison A, Hecker H, Calatzis A, Solomon C. An evaluation of cyclooxygenase-1 inhibition before coronary artery surgery: aggregometry versus patient self-reporting. Anesth Analg 2008; 107: 1791-7.
- 25 Rahe-Meyer N, Winterhalter M, Boden A, Froemke C, Piepenbrock S, Calatzis A, Solomon C. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand 2009; 53: 168-75.
- 26 Solomon C, Hartmann J, Osthaus A, Schochl H, Raymondos K, Koppert W, Rahe-Meyer N. Platelet concentrates transfusion in cardiac surgery in relation to preoperative point-of-care assessment of platelet adhesion and aggregation. Platelets 2010.
- 27 Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45: 911-9.
- 28 Picker SM, Oustianskaia L, Schneider V, Gathof BS. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B(2)) for pathogen-reduction. Vox Sang 2009; 97: 26-33.
- 29 Picker SM, Schneider V, Gathof BS. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009.
- 30 Hornsey VS, Drummond O, Morrison A, McMillan L, MacGregor IR, Prowse CV. Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins. Transfusion 2009; 49: 2167-72.
- 31 Larrea L, Calabuig M, Roldan V, Rivera J, Tsai HM, Vicente V, Roig R. The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci 2009; 41: 199-204.
- 32 Bihm DJ, Ettinger A, Buytaert-Hoefen KA, Hendrix BK, Maldonado-Codina G, Rock G, Giclas PC, Goodrich RP. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C. Vox Sang 2009.
- 33 Smith J, Rock G. Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma. Transfusion 2009.
- 34 Escolar G, Garrido M, Mazzara R, Castillo R, Ordinas A. Experimental basis for the use of red cell transfusion in the management of anemic-thrombocytopenic patients. Transfusion 1988; 28: 406-11.
- 35 Uijttewaal WS, Nijhof EJ, Bronkhorst PJ, Den Hartog E, Heethaar RM. Near-wall excess of platelets induced by lateral migration of erythrocytes in flowing blood. Am J Physiol 1993; 264: H1239-H1244.
- 36 Peyrou V, Lormeau JC, Herault JP, Gaich C, Pfliegger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost 1999; 81: 400-6.
- 37 Joist JH, Bauman JE, Sutera SP. Platelet adhesion and aggregation in pulsatile shear flow: effects of red blood cells. Thromb Res 1998; 92: S47-S52.
- 38 Reimers RC, Sutera SP, Joist JH. Potentiation by red blood cells of shear-induced platelet aggregation: relative importance of chemical and physical mechanisms. Blood 1984; 64: 1200-6.
- 39 Valles J, Santos MT, Aznar J, Marcus AJ, Martinez-Sales V, Portoles M, Broekman MJ, Safier LB. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 1991; 78: 154-62.
- 40 Valeri CR, Cassidy G, Pivacek LE, Ragno G, Lieberthal W, Crowley JP, Khuri SF, Loscalzo J. Anemia-induced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001; 41: 977-83.
- 41 Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006; 32(Suppl 1): 49-60.
- 42 Hardy JF, de Moerloose P, Samama CM. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth 2006; 53: S40-S58.
- 43 Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 2008; 65: 951-60.
- 44 Guide to the preparation, use and quality assurance of blood components. 14th ed. Recommendation No. R(95)15. Strasbourg: Council of Europe Publishing; 2008.
- 45 Larsen CP, Ezligini F, Hermansen NO, Kjeldsen-Kragh J. Six years' experience of using the BacT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false-negative results. Vox Sang 2005; 88: 93-7.
- 46 Svendsen MS, Rojkjaer R, Kristensen AT, Salado-Jimena JA, Kjalke M, Johansson PI. Impairment of the hemostatic potential of platelets during storage as evaluated by flow cytometry, thrombin generation, and thrombelastography under conditions promoting formation of coated platelets. Transfusion 2007; 47: 2057-65.
- 47 Li J, de Korte D, Woolum MD, Ruane PH, Keil SD, Lockerbie O, McLean R, Goodrich RP. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang 2004; 87: 82-90.
- 48 AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41.
- 49 Ostrowski SR, Bochsen L, Salado-Jimena JA, Ullum H, Reynaerts I, Goodrich RP, Johansson PI. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010; 50: 2210-9.
- 50 Kang YG, Martin DJ, Marquez J, Lewis JH, Bontempo FA, Shaw BW, Jr, Starzl TE, Winter PM. Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg 1985; 64: 888-96.
- 51 McNicol PL, Liu G, Harley ID, McCall PR, Przybylowski GM, Bowkett J, Angus PW, Hardy KJ, Jones RM. Patterns of coagulopathy during liver transplantation: experience with the first 75 cases using thrombelastography. Anaesth Intensive Care 1994; 22: 659-65.
- 52 Spiess BD, Gillies BS, Chandler W, Verrier E. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995; 9: 168-73.
- 53 Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: 312-9.
- 54 Manikappa S, Mehta Y, Juneja R, Trehan N. Changes in transfusion therapy guided by thromboelastograph in cardiac surgery. Ann Card Anaesth 2001; 4: 21-7.
- 55 Anderson L, Quasim I, Soutar R, Steven M, Macfie A, Korte W. An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. Transfus Med 2006; 16: 31-9.
- 56 Welsby IJ, Jiao K, Ortel TL, Brudney CS, Roche AM, Bennett-Guerrero E, Gan TJ. The kaolin-activated thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2006; 20: 531-5.
- 57 Carroll RC, Craft RM, Langdon RJ, Clanton CR, Snider CC, Wellons DD, Dakin PA, Lawson CM, Enderson BL, Kurek SJ. Early evaluation of acute traumatic coagulopathy by thrombelastography. Transl Res 2009; 154: 34-9.
- 58 Levrat A, Gros A, Rugeri L, Inaba K, Floccard B, Negrier C, David JS. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100: 792-7.
- 59 Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67: 125-31.
- 60 Schoechl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, Kozek-Langenecker S, Solomon C. Goal-directed coagulation management of major trauma patients using rotation thromboelastometry (ROTEM)-guided administration of fibrinogen and prothrombin complex concentrate. Crit Care 2010; 14: R55.
- 61 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22: 1381-9.
- 62 Hoffman MM, Monroe DM. Rethinking the coagulation cascade. Curr Hematol Rep 2005; 4: 391-6.
- 63 Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2: 402-13.
- 64 Kawasaki J, Katori N, Kodaka M, Miyao H, Tanaka KA. Electron microscopic evaluations of clot morphology during thrombelastography. Anesth Analg 2004; 99: 1440-4.
- 65 Cardigan R, Williamson LM. The quality of platelets after storage for 7 days. Transfus Med 2003; 13: 173-87.
- 66 A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. The Mirasol Clinical Evaluation Study Group. Transfusion 2010; 50: 2362-75.
- 67 Goodrich RP, Li J, Pieters H, Crookes R, Roodt J, Heyns AP. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 2006; 90: 279-85.
- 68 Liaw PC, Esmon CT, Kahnamoui K, Schmidt S, Kahnamoui S, Ferrell G, Beaudin S, Julian JA, Weitz JI, Crowther M, Loeb M, Cook D. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2004; 104: 3958-64.
- 69 Eugster M, Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost 2005; 94: 1213-8.
- 70 Reinhart WH, Zehnder L, Schulzki T. Stored erythrocytes have less capacity than normal erythrocytes to support primary haemostasis. Thromb Haemost 2009; 101: 720-3.
- 71 Mackie IJ, Jones R, Machin SJ. Platelet impedance aggregation in whole blood and its inhibition by antiplatelet drugs. J Clin Pathol 1984; 37: 874-8.
- 72 Muller MR, Salat A, Pulaki S, Stangl P, Ergun E, Schreiner W, Losert U, Wolner E. Influence of hematocrit and platelet count on impedance and reactivity of whole blood for electrical aggregometry. J Pharmacol Toxicol Methods 1995; 34: 17-22.
- 73 Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18: 199-206.
- 74 Munnix IC, Cosemans JM, Auger JM, Heemskerk JW. Platelet response heterogeneity in thrombus formation. Thromb Haemost 2009; 102: 1149-56.